Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies
What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a medicine called ravulizumab, a treatment approv...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2024-10-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | What is this summary about?
Generalized myasthenia gravis (often shortened to gMG) is a rare health
condition that causes muscular weakness. This summary gives an
overview of three published articles that report the results of research
studies of a medicine called ravulizumab, a treatment approved for
adults with gMG. These studies are:
• The CHAMPION MG study.
• The CHAMPION MG extension study.
• A study of how the body processes and responds to ravulizumab
(known as pharmacokinetics and pharmacodynamics).
These studies looked at how effective and safe ravulizumab is for
people with gMG. |
|---|---|
| ISSN: | 2042-6313 |